PMID- 9059669
OWN - NLM
STAT- MEDLINE
DCOM- 19970523
LR  - 20190201
IS  - 0001-5555 (Print)
IS  - 0001-5555 (Linking)
VI  - 77
IP  - 1
DP  - 1997 Jan
TI  - Skin-derived antileukoproteinase (SKALP) and epidermal fatty acid-binding protein 
      (E-FABP): two novel markers of the psoriatic phenotype that respond 
      differentially to topical steroid.
PG  - 14-9
AB  - Recently we have described two novel markers for disturbed epidermal 
      differentiation, which are strongly upregulated in psoriatic epidermis: 
      skin-derived antileukoproteinase (SKALP) and epidermal fatty acid-binding protein 
      (E-FABP). No data are available on the kinetics of SKALP and E-FABP expression in 
      vivo and the relation with epidermal growth and differentiation. We used 
      treatment of lesional psoriatic skin with topical steroid as a model to correlate 
      the expression pattern of SKALP and E-FABP with known cell biological events 
      during regression of the psoriatic lesion. Expression of these markers was 
      studied using immunohistochemistry and Northern blot analysis. After 4 weeks of 
      treatment a substantial clinical improvement was induced by the topical steroid, 
      whereas no significant improvement had occurred at the placebo-treated sides. The 
      expression of SKALP following treatment with steroid was nearly undetectable both 
      at the protein and mRNA level. Mitotic activity, as measured by Ki-67 staining, 
      and cytokeratin 16 expression were downregulated to normal levels in the 
      steroid-treated epidermis. In contrast, although there was a marked decrease of 
      E-FABP mRNA, the staining pattern for E-FABP at the protein level was not 
      affected. After 4 weeks of treatment with steroid the complete suprabasal 
      compartment remained positive, even after considerable clinical improvement of 
      the lesion. We conclude that SKALP and cytokeratin 16 are markers that are 
      downregulated even before complete macroscopic clearance of the lesion. The 
      kinetics of E-FABP expression is distinct from the other molecules and lags 
      behind the clinical signs of psoriasis.
FAU - Kuijpers, A L
AU  - Kuijpers AL
AD  - Department of Dermatology, University Hospital Nijmegen, The Netherlands.
FAU - Bergers, M
AU  - Bergers M
FAU - Siegenthaler, G
AU  - Siegenthaler G
FAU - Zeeuwen, P L
AU  - Zeeuwen PL
FAU - van de Kerkhof, P C
AU  - van de Kerkhof PC
FAU - Schalkwijk, J
AU  - Schalkwijk J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Carrier Proteins)
RN  - 0 (FABP5 protein, human)
RN  - 0 (FABP7 protein, human)
RN  - 0 (Fatty Acid-Binding Protein 7)
RN  - 0 (Fatty Acid-Binding Proteins)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Myelin P2 Protein)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Proteinase Inhibitory Proteins, Secretory)
RN  - 0 (Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 68238-35-7 (Keratins)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Administration, Topical
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*pharmacology/therapeutic use
MH  - Biomarkers/*analysis
MH  - Blotting, Northern
MH  - Carrier Proteins/*analysis
MH  - Double-Blind Method
MH  - Epidermis/*chemistry
MH  - Fatty Acid-Binding Protein 7
MH  - Fatty Acid-Binding Proteins
MH  - Female
MH  - Humans
MH  - Hydrocortisone
MH  - Immunohistochemistry
MH  - Keratins/analysis
MH  - Ki-67 Antigen/analysis
MH  - Male
MH  - Middle Aged
MH  - Myelin P2 Protein/*analysis
MH  - *Neoplasm Proteins
MH  - Phenotype
MH  - Proteinase Inhibitory Proteins, Secretory
MH  - Proteins/*analysis
MH  - Psoriasis/*drug therapy/*metabolism
MH  - RNA, Messenger/analysis
MH  - *Tumor Suppressor Proteins
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.2340/0001555577014019 [doi]
PST - ppublish
SO  - Acta Derm Venereol. 1997 Jan;77(1):14-9. doi: 10.2340/0001555577014019.